Jun 1, 2018Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) Label Expansion
Aratana submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) to expand the NOCITA label to include its use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy.
May 22, 2018
The Company plans on presenting at Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30 p.m. ET in New York City.
May 21, 2018Aratana Therapeutics Appoints Craig Barbarosh and Lowell Robinson to its Board of Directors in Cooperation Agreement with Engaged Capital
The Company has appointed Craig Barbarosh and Lowell Robinson to its Board of Directors in connection with a cooperation agreement with Engaged Capital, LLC.
May 3, 2018
Aratana announced its first quarter 2018 financial results, reporting total net revenues of $4.0 million and a net loss of $8.5 million or $0.19 diluted loss per share.
Apr 12, 2018
The Company will host a live conference call on Friday, May 4, 2018 at 8:30 a.m. ET to discuss financial results from the first quarter ended March 31, 2018.
Apr 5, 2018
Aratana confirmed it received a notice of nomination of three director candidates for election to the Company's Board of Directors from Engaged Capital, LLC and certain of its affiliated entities.
Mar 13, 2018
Aratana announced its fourth quarter and full year 2017 financial results, reporting total net revenues of $10.4 million and a net loss of $15.6 million or $0.37 diluted loss per share.
Mar 2, 2018
The Company plans on attending Cowen and Barclays investment conferences.
Mar 1, 2018
Aratana announced it licensed exclusive, worldwide rights to develop and commercialize AT-019 from AskAt Inc. AT-019 is a potent and innovative EP4 receptor antagonist with potential in pain, inflammation and other indications.
Feb 13, 2018
Aratana will host a live conference call on Wednesday, March 14, 2018 at 8:30 a.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2017.